Fecal microbiota transplantation (FMT) has been reported to exert potential therapeutic value in gut microbiota dysbiosis.During FMT, the fecal material is transferred from a healthy donor into the gastrointestinal tract of a recipient via naso-gastric tube, enema, colonoscopy or oral capsules, aiming to reconstruct intestinal flora, ameliorate the dysbiotic state, control inflammation and modulate the immunity.FMT is recognized as a high-efficient and safe treatment option for recurrent clostridium difficile infection.It has been approved by the United States Food and Drug Administration for clinical use in the USA.FMT is a safe and effective treatment for patients with infla-mmatory bowel disease or autism spectrum disorder.